Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06282458 · ClinicalTrials.gov registry record · Phase 2

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

A Phase 2 study, sponsored by Veru.

Completed
Registry status
Phase 2
Development phase
168
Enrollment target

NCT06282458: Completed Phase 2 study, sponsored by Veru.

NCT06282458 is a Phase 2 study that has completed, run by Veru. The registered enrollment target is 168 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06282458, a Phase 2 study, has completed, sponsored by Veru.

COMPLETED
Registry status
Phase 2
Development phase
168 participants
Enrollment target

Study Summary

The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.

Primary Outcome

To determine the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists (percent change in total lean mass) at 112 days.

Interventions

  • DRUG Semaglutide
  • DRUG Enobosarm

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2024-04-29
Est. Completion 2025-08-22
Phase Phase 2
Veru

10 total trials

What the finished NCT06282458 record still lists

NCT06282458 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher).

The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.

NCT06282458 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06282458 about?

NCT06282458 is a clinical study titled "Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt". The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.

What is the current status of trial NCT06282458?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2024-04-29. Estimated completion is 2025-08-22.

What interventions are being tested in trial NCT06282458?

The interventions under investigation include: Semaglutide (DRUG), Enobosarm (DRUG).

Who is sponsoring clinical trial NCT06282458?

This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06282458's enrollment target sits among peer trials

168 403rd of 2000 higher than 1,595 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02118922 · 168 participants

    A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

  • NCT03536897 · 168 participants

    IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

  • NCT04078230 · 168 participants · NA

    Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

  • NCT04159168 · 168 participants · NA

    Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06282458, the US trial registry maintained by the National Library of Medicine. NCT06282458 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.